



JFW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below for efficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 9, 2007

Signature:

Joseph A. Williams, Jr.

Docket No.: 30572/42052
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Andreas Greinacher et al.

Application No.: 10/578,452

Confirmation No.: Not Yet Assigned

Filed: May 5, 2006

Art Unit: Not Yet Assigned

For: Use of MRP4-Inhibitors for the Treatment
and/or Prophylaxis of Cardiovascular Diseases

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30572/42052. A duplicate copy of this paper is enclosed.

Dated: January 9, 2007

Respectfully submitted,

By 

Joseph A. Williams, Jr.

Registration No.: 38,659

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/578,452
Filing Date	May 5, 2006
First Named Inventor	Andreas Greinacher
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	30572/42052

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		4,287,202	09-01-1981	Horrobin	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		FR-2 353 285	12-30-1977	Lab Doms		
		WO 00/58471	10-05-2000	Schuetz et al.		
		WO 02/03993	01-17-2002	Jedlitschky et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Born, "Functional Physiology of Platelets," Human Blood Coagulation 168-201	
		Cheitlin, et al. "Use of Sildenafil (Viagra) in Patients with Cardiovascular Disease" Circulation, American Heart Association, 99(1):168-177 (1999)	
		Chen et al., "Transport of Cyclic Nucleotide and Estradiol 17-β-D-Glucuronide by Multidrug Resistance Protein 4," The Journal of Biological Chemistry, 276(36):33747-33754 (2001)	
		Diener et al., "European Stroke Prevention Study 2," Nervenheilkunde, 18:380-90 (1999)	
		Feliste et al., "Effect of PCR 4099 on ADP-induced calcium movements and phosphatidic acid production in rat platelets," Biochem Pharmacol. 37(13):2559-64 (1988)	
		Han et al., "Effects of Leukotriene D4 and its specific antagonist L-660, 711 in isolated rat heart after myocardial infarction," Journal of Molecular and Cellular Cardiology, 24(5):S51 (1992)	
		Jedlitschky et al., "The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage," Blood 104(12):3603-3610 (2004)	
		Jones et al., "Pharmacology of L-660, 711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist," Can. J. Physiol. Pharmacol. 67:17-28 (1989)	
		Keppler et al., "Transport Function and Substrate Specificity of Multidrug Resistance Protein," Methods in Enzymology 292:607-616 (1998)	
		Kool et al., "Analysis of Expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, Homologues of the Multidrug Resistance-associated Protein Gene (MRP1), in Human Cancer Cell Lines," Cancer Research 57:3537-3547 (1997)	
		Kroemer et al., "The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and located in granules, indicating a role in mediator storage," Circulation, 108(17):IV-42 (2003)	

Examiner Signature	Date Considered
-----------------------	--------------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/578,452
				Filing Date	May 5, 2006
				First Named Inventor	Andreas Greinacher
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	30572/42052

		Lal et al., "Trequinsin, a Potent New Antihypertensive Vasodilator in the Series of 2-(Arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]iso-quinolin-4-ones," Journal of Medicinal Chemistry, American Chemical Society, 11(27):1470-1480 (1984)	
		Laloo et al., "Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2)," BMC Medicine 2(16):1-12 (2004)	
		Matzdorff et al., "Quantitative assessment of platelets, platelet microparticles, and platelet aggregates with flow cytometry," J Lab Clin Med, 131(6):507-517	
		Mitani et al., "Expression of multidrug resistance protein 4 and 5 in the porcine coronary and pulmonary arteries," European Journal of Pharmacology 466:223-224 (2003)	
		Mondoro et al., "Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization," Blood 96(7):2487-2495	
		Parks et al., "Comparative effect of ibuprofen on endothelial and platelet prostaglandin synthesis," J. Pharmacol Exp. Ther. 219(2):415-9 (1981)	
		Reid et al., "Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5," Molecular Pharmacology, 63(5):1094-1103 (2003)	
		Reid et al., "The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs," Proceedings of the National Academy of Sciences of USA, National Academy of Science 100(16):9244-9249 (2003)	
		Simel, "Antiplatelet Agents Reduce Risks for Death, Stroke, Myocardial Infarction, Deep Venous Thrombosis, and Arterial Occlusion," Annals of Internal Medicine 521(1):4-6 (1994)	
		White et al., "Assessment of Lumiaggregometry for Research and Clinical Laboratories," Thrombosis and Haemostasis 67(5):572-577 (1992)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--